Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors

Hisato Igarashi, Tetsuhide Ito, Samuel A. Mantey, Tapas K. Pradhan, Wei Hou, David H. Coy, Robert T. Jensen

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/ VPAC2to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1-and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala 2,8,9,11,19,22,24,25,27,28)VIP and (Ala2,8,9,11,19,24-28) VIP] were found to have >2000-and >600-fold selectivity for hVPAC 1. None of the nine analogs had hVPAC2 selectivity. However, two simplified analogs [(Ala2,8,9, 16,19,24)VIP and (Ala2,8,9,16,19,24,25)VIP] retained high affinity and potency for both hVPACs. 125I-[Ala2,8,9,16,19,24,25]VIP was much more metabolically stable than 125I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.

Original languageEnglish
Pages (from-to)370-381
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume315
Issue number1
DOIs
Publication statusPublished - Oct 1 2005

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide Receptors
Pituitary Adenylate Cyclase-Activating Polypeptide
Adenylyl Cyclases
Neurotransmitter Agents
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. / Igarashi, Hisato; Ito, Tetsuhide; Mantey, Samuel A.; Pradhan, Tapas K.; Hou, Wei; Coy, David H.; Jensen, Robert T.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 315, No. 1, 01.10.2005, p. 370-381.

Research output: Contribution to journalArticle

@article{92bec41d76e44ef4ba433efa3e2de1f0,
title = "Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors",
abstract = "Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/ VPAC2to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1-and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala 2,8,9,11,19,22,24,25,27,28)VIP and (Ala2,8,9,11,19,24-28) VIP] were found to have >2000-and >600-fold selectivity for hVPAC 1. None of the nine analogs had hVPAC2 selectivity. However, two simplified analogs [(Ala2,8,9, 16,19,24)VIP and (Ala2,8,9,16,19,24,25)VIP] retained high affinity and potency for both hVPACs. 125I-[Ala2,8,9,16,19,24,25]VIP was much more metabolically stable than 125I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.",
author = "Hisato Igarashi and Tetsuhide Ito and Mantey, {Samuel A.} and Pradhan, {Tapas K.} and Wei Hou and Coy, {David H.} and Jensen, {Robert T.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1124/jpet.105.088823",
language = "English",
volume = "315",
pages = "370--381",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors

AU - Igarashi, Hisato

AU - Ito, Tetsuhide

AU - Mantey, Samuel A.

AU - Pradhan, Tapas K.

AU - Hou, Wei

AU - Coy, David H.

AU - Jensen, Robert T.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/ VPAC2to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1-and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala 2,8,9,11,19,22,24,25,27,28)VIP and (Ala2,8,9,11,19,24-28) VIP] were found to have >2000-and >600-fold selectivity for hVPAC 1. None of the nine analogs had hVPAC2 selectivity. However, two simplified analogs [(Ala2,8,9, 16,19,24)VIP and (Ala2,8,9,16,19,24,25)VIP] retained high affinity and potency for both hVPACs. 125I-[Ala2,8,9,16,19,24,25]VIP was much more metabolically stable than 125I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.

AB - Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/ VPAC2to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1-and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala 2,8,9,11,19,22,24,25,27,28)VIP and (Ala2,8,9,11,19,24-28) VIP] were found to have >2000-and >600-fold selectivity for hVPAC 1. None of the nine analogs had hVPAC2 selectivity. However, two simplified analogs [(Ala2,8,9, 16,19,24)VIP and (Ala2,8,9,16,19,24,25)VIP] retained high affinity and potency for both hVPACs. 125I-[Ala2,8,9,16,19,24,25]VIP was much more metabolically stable than 125I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=25644444563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644444563&partnerID=8YFLogxK

U2 - 10.1124/jpet.105.088823

DO - 10.1124/jpet.105.088823

M3 - Article

VL - 315

SP - 370

EP - 381

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -